We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+5.98%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$5.26B
AUM Growth
+$740M
Cap. Flow
+$520M
Cap. Flow %
9.89%
Top 10 Hldgs %
40.34%
Holding
110
New
23
Increased
31
Reduced
29
Closed
25

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$178M
2
AGN
Allergan plc
AGN
+$168M
3
GILD icon
Gilead Sciences
GILD
+$89.7M
4
BABA icon
Alibaba
BABA
+$67.2M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$66.5M

Top Sells

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$93.9M
2
BPMC
Blueprint Medicines
BPMC
+$77.2M
3
ARNA
Arena Pharmaceuticals Inc
ARNA
+$73.7M
4
PFE icon
Pfizer
PFE
+$50.2M
5
ELV icon
Elevance Health
ELV
+$42.9M

Sector Composition

Rank Sector Weight
1 Healthcare 55.27%
2 Technology 8.75%
3 Communication Services 4%
4 Consumer Discretionary 3.22%
5 Financials 2.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QQQ icon
1
PUT
Invesco QQQ Trust
QQQ
$470B
$707M 13.43%
3,787,600
+1,751,900
+86% +$322M
AGN
2
DELISTED
Allergan plc
AGN
$299M 5.68%
1,785,597
+1,210,760
+211% +$168M
BMRN icon
3
BioMarin Pharmaceuticals
BMRN
$11.5B
$178M 3.38%
+2,079,388
New +$178M
AMGN icon
4
PUT
Amgen
AMGN
$199B
$153M 2.91%
+831,900
New +$149M
HUM icon
5
Humana
HUM
$48.1B
$149M 2.83%
562,177
+197,704
+54% +$50.1M
ZBH icon
6
Zimmer Biomet
ZBH
$17.1B
$137M 2.61%
1,200,459
+220,676
+23% +$25.8M
WCG
7
DELISTED
Wellcare Health Plans, Inc.
WCG
$137M 2.6%
480,244
+147,410
+44% +$40.6M
PEN icon
8
Penumbra
PEN
$12.5B
$123M 2.35%
771,799
+44,742
+6% +$6.46M
BOLD
9
DELISTED
Audentes Therapeutics, Inc
BOLD
$122M 2.32%
3,228,679
+1,198,198
+59% +$46M
QCOM icon
10
CALL
Qualcomm
QCOM
$187B
$117M 2.22%
1,538,900
-1,739,700
-53% -$127M
ARNA
11
DELISTED
Arena Pharmaceuticals Inc
ARNA
$107M 2.04%
1,828,378
-1,426,852
-44% -$73.7M
IQV icon
12
IQVIA
IQV
$33.2B
$103M 1.95%
638,326
+361,517
+131% +$50.7M
ICUI icon
13
ICU Medical
ICUI
$3.96B
$97.4M 1.85%
386,592
+11,732
+3% +$2.72M
BABA icon
14
Alibaba
BABA
$278B
$96.8M 1.84%
571,376
+389,164
+214% +$67.2M
GILD icon
15
Gilead Sciences
GILD
$164B
$92.2M 1.75%
+1,364,288
New +$89.7M
CRM icon
16
Salesforce
CRM
$135B
$90.8M 1.73%
598,759
+393,361
+192% +$61.6M
MYOK
17
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$89.1M 1.69%
1,777,409
+176,102
+11% +$8.57M
SYK icon
18
Stryker
SYK
$119B
$88.2M 1.67%
428,849
-150,595
-26% -$28.8M
HCA icon
19
HCA Healthcare
HCA
$82.9B
$85.1M 1.62%
629,767
+342,816
+119% +$43.3M
EW icon
20
Edwards Lifesciences
EW
$48.6B
$84.3M 1.6%
1,369,077
+288,156
+27% +$17.4M
SRPT icon
21
Sarepta Therapeutics
SRPT
$1.72B
$83.1M 1.58%
+546,786
New +$66.5M
MOH icon
22
Molina Healthcare
MOH
$11.7B
$77.4M 1.47%
540,898
+40,360
+8% +$5.53M
ESPR
23
DELISTED
Esperion Therapeutics
ESPR
$72.3M 1.37%
1,555,112
-71,967
-4% -$3.38M
PFE icon
24
Pfizer
PFE
$143B
$70.7M 1.34%
1,720,850
-1,265,233
-42% -$50.2M
MCHP icon
25
Microchip Technology
MCHP
$45.9B
$65.3M 1.24%
1,507,058
-546,584
-27% -$24.3M
1
2 3 4 5

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
CPRC
Consolidated Portfolio Review Corp Woodbury, New York $1.1B AUM 8.96% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.1B AUM 30.57% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return

PFM Health Sciences's Q2 2019 Portfolio in Review

As of Q2 2019, PFM Health Sciences held 110 positions worth $5.26B, up 16% from $4.52B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

PFM Health Sciences deployed $520M of net new capital in Q2 2019, opening 23 new positions and adding to 31 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 2,079,388 shares worth $178M.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, up from 55% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was UnitedHealth, an estimated $93.9M trimmed.

  • PFM Health Sciences's largest Q2 2019 buy was BioMarin Pharmaceuticals: 2,079,388 shares worth $178M.
  • PFM Health Sciences added most to Allergan plc in Q2 2019, an estimated $168M increase.
  • PFM Health Sciences's biggest Q2 2019 reduction was UnitedHealth, cutting an estimated $93.9M.
  • PFM Health Sciences fully exited Blueprint Medicines in Q2 2019, selling an estimated $77.2M.
  • PFM Health Sciences's ten largest holdings make up 40% of its $5.26B portfolio in Q2 2019.
  • PFM Health Sciences opened 23 new positions and closed 25 in Q2 2019.
  • PFM Health Sciences's portfolio value rose 16% quarter-over-quarter to $5.26B.

Based on PFM Health Sciences's 13F filing for Q2 2019, filed 14 Aug 2019.